AR and cancer: Etrumadenant is a dual A2A AR/A2B AR antagonist currently in clinical trials for cancer [228,229] but is reported here as an example of a dual-targeting ligand that, due to the complex regulation in the CNS by different AR subtypes, could be an effective strategy for the treatment of neurodegenerative diseases.